Abstract: This invention is for a simple device for converting the oxygen in air to ozone which then passes into the combustion chamber of a diesel fueled engine. When this device is used the amount of energy obtained from the diesel is greatly increased.

Abstract: A method of reducing buffer overflow in a cellular radio network caused by a transfer of data from a buffer in a first cell to a buffer in a second cell when a handover of mobile equipment from said first cell to said second cell occurs. The method comprises temporarily increasing an amount of temporary buffer space required to handle data transferred from the buffer of the first cell to the buffer of the second cell. In one embodiment of the method, prior to increasing the amount of temporary buffer space, the amount of temporary buffer space required is calculated.

Abstract: The invention relates to a process for the preparation of 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno-[2,3-b][1,5]benzodiazepine (olanzapine) of the formula (I) by reacting 4-amino-2-methyl-10H-thieno [2,3-b][1/5]benzodiazepine hydrochloride of the formula (II) with N-methylpiperazine in an organic solvent, which comprises carrying out the reaction in the mixture of toluene and 1,3-dimethyl-2-imidazolidinone. The invention also encompasses new 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno [2,3-b][1,5]benzodiazepine dihydrochloride trihydrate of the formula (IB), the preparation thereof and pharmaceutical compositions comprising said new compound.

Abstract: Piperazinylalkylthiopyrimidine derivatives of formula (I), a process for preparing them, and pharmaceutical compositions containing them as active substances. The compounds are useful for the treatment of central nervous system disorders, especially anxiety.

Abstract: The invention refers to novel piperazinylalkylthiopyrimidine derivatives of formula (I) being suitable for the treatment of diseases due to pathological alterations of the central nervous system, pharmaceutical compositions containing the above derivatives, and a process for the preparation of the novel compounds.

Abstract: The compounds of the Formula (I) ##STR1## wherein R.sub.1 is a C.sub.18-24 alkenyl containing at least two double bonds, or --(CH2)n --CH(NH2)m --COOHX is 0, NH or C.sub.1-4 alkyl-N,Y is CONH.sub.2, COOH or COOMe, wherein Me is hydrogen metal, andR.sub.2 is a side chain of a any amino acid except L-GLU or L-ASP at .alpha.-position or a group of Formula--(CH.sub.2).sub.k --C.sub.6 H.sub.3 --(A).sub.2 (II),--(CH.sub.2).sub.n --X--(CH.sub.2).sub.m --X--M (III)whereink is zero or an integer of 1,n is zero or an integer of 1 to 3,m is zero or an integer of 1 to 4,A is hydroxyl or one A is hydroxyl and the other A is hydrogen.M is H or R.sub.1 --CO andX and R.sub.1 are as defined aboveand their salts having tyrosine kinase inhibitor activity can be used as antitumor agents.